Acción ATNM ACTINIUM PHARMACEUTICALS, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Actinium Pharmaceuticals, Inc.

Acciones

ATNM

US00507W2061

Mercado cerrado - Nyse
Otros sitios de cotización
 22:00:00 26/04/2024 		Varia. Cinco días. Varia. 1 de enero.
6,87 USD +4,73 % Gráfico intradía de Actinium Pharmaceuticals, Inc. +0,29 % +35,24 %
26/04 Actinium Pharmaceuticals, Inc. Resultados del primer trimestre finalizado el 31 de marzo de 2024 CI
18/04 Actinium Pharmaceuticals, Inc. destaca en la Reunión Anual Europea de Trasplante de Médula Ósea la capacidad de Iomab-B para superar la mutación TP53 de alto riesgo, lo que se traduce en una mejora significativa de la supervivencia global en pacientes con LMA activa recidivante refractaria CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML
Actinium Pharmaceuticals, Inc. Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest
Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation
InvestorBrandMedia: Wall Street Bulls Eye a 290% Upside on Actinium Pharmaceuticals, Inc. (NYSEAMERICAN: ATNM) Amidst Groundbreaking Cancer Therapy Innovations
Actinium Pharmaceuticals, Inc. Announces Iomab-B Phase 3 Sierra Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation At the 50Th European Bone Marrow Transplant Annual Meeting
Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey
Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
Actinium Pharmaceuticals Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with FDA Approved Commercial CAR T-Cell Therapy
InvestorBrandMedia: FDA Approves Vertex Pharmaceuticals (NASDAQ:VRTX) VX-407 for Phase I Study in Groundbreaking Move Against Polycystic Kidney Disease"
InvestorBrandMedia: Actinium Pharmaceuticals Inc (ATNM) Targets Breakthrough in Cancer Therapy: Proprietary Production of Vital Isotope Sparks Industry Buzz and Share Surge
InvestorBrandMedia: Actinium Pharmaceuticals Inc. (ATNM) Leads Breakthroughs in Targeted Radiotherapy with Iomab-B and Strategic Production of Actinium-225
Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial
Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings
Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings, Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
Actinium s Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation
Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting and Exposition
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción ATNM
  4. Noticias Actinium Pharmaceuticals, Inc.
  5. Otros idiomas